ADDED
Our growth depends on the timely development and commercialization, and customer acceptance, of new and enhanced products and services (in this Annual Report, references to products and services also includes software), based on technological innovation.
Our growth also suffers when the markets into which we sell our products and services decline, do not grow as anticipated or experience cyclicality.
For example, elections can result in significant political shifts and/or disruptions, and the 2025 change in the U.S.
1 administration as well as recent Supreme Court decisions have resulted in policy, regulatory and economic changes, challenges and uncertainty, including with respect to tariffs and healthcare-related topics.
Our acquisition of businesses (including our pending acquisition of Masimo Corporation), investments, joint ventures and other strategic relationships can also negatively impact our business and financial statements and our indemnification rights may not fully protect us from liabilities related thereto.
Financial and Tax Risks From time to time our outstanding debt has increased significantly as a result of acquisitions and other factors, and we expect to incur additional debt.
Our business research and development, manufacturing, sales, distribution, service and administrative facilities are located in approximately 50 countries.
While the operating companies that make up Danaher have changed over time, DBS continues to be the guiding philosophy for the Company.
Sales in 2025 by geographic destination (geographic destination refers to the geographic area where the final sale to the Company s unaffiliated customer is made) and by revenue type (revenue type refers to categorizing the Company s products between those typically sold to a customer on a recurring basis and those typically sold to a customer on a nonrecurring basis) as a percentage of total 2025 sales were: Sales in North America includes 41% in the United States.
4 BIOTECHNOLOGY The Biotechnology segment offers a broad range of equipment, consumables, software and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines.
REMOVED
and other countries may result in significant political shifts and/or disruptions, including changes in the regulatory environment, and recent Supreme Court decisions in the U.S.
1 Uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products may result in harm to our business and reputation.
Our acquisition of businesses, investments, joint ventures and other strategic relationships could also negatively impact our business and financial statements and our indemnification rights may not fully protect us from liabilities related thereto.
Our success depends on our ability to recruit, retain and motivate talented employees representing diverse backgrounds, experiences and skill sets.
Our restructuring actions can have long-term adverse effects on our business and financial statements.
Financial and Tax Risks From time to time our outstanding debt has increased significantly as a result of acquisitions, and we may incur additional debt.
Our business research and development, manufacturing, sales, distribution, service and administrative facilities are located in more than 50 countries.
While the operating companies that make up Danaher have changed, DBS continues to be the guiding philosophy for the Company.
Sales in 2024 by geographic destination (geographic destination refers to the geographic area where the final sale to the Company s unaffiliated customer is made) as a percentage of total 2024 sales were: North America, 43% (including 42% in the United States); Western Europe, 23%; other developed markets, 5%; and high-growth markets, 29%.
BIOTECHNOLOGY The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines.